Pharvaris (NASDAQ:PHVS) CEO Sells $90,265.40 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,291 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $39.40, for a total transaction of $90,265.40. Following the sale, the chief executive officer directly owned 128,334 shares in the company, valued at $5,056,359.60. This trade represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Friday, August 14th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $34.77, for a total transaction of $79,692.84.

Pharvaris Stock Performance

NASDAQ:PHVS opened at $38.00 on Friday. The stock’s fifty day moving average price is $35.35 and its two-hundred day moving average price is $31.69. Pharvaris N.V. has a 52-week low of $20.65 and a 52-week high of $43.25. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -12.46 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, equities analysts predict that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on PHVS. New Street Research set a $60.00 price objective on Pharvaris in a report on Friday, August 14th. Wells Fargo & Company lifted their price target on shares of Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. Leerink Partners boosted their price target on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Wedbush increased their price objective on shares of Pharvaris from $42.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Finally, Morgan Stanley raised their price objective on shares of Pharvaris from $46.00 to $62.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.87.

Hedge Funds Weigh In On Pharvaris

Several hedge funds have recently added to or reduced their stakes in PHVS. Alyeska Investment Group L.P. raised its position in shares of Pharvaris by 225.5% in the 2nd quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock valued at $14,068,000 after acquiring an additional 281,829 shares during the period. BlackRock Inc. acquired a new position in Pharvaris during the second quarter valued at approximately $26,677,000. Seven Fleet Capital Management LP increased its stake in Pharvaris by 472.3% in the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after purchasing an additional 261,355 shares in the last quarter. PSP Research LLC acquired a new stake in Pharvaris in the fourth quarter worth $569,000. Finally, DV Trading LLC acquired a new stake in Pharvaris in the first quarter worth $4,067,000.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.